This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Here's Why You Should Hold on to BD (BDX) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about BD (BDX) owing to a few regulatory approvals and strategic deals.
S&P 500 Likely to Trade Rangebound in September: 5 Picks
by Nalak Das
We have narrowed our search to five S&P 500 stocks that have popped year to date despite the index's bloodbath. These are: ADM, CTVA, MCK, MPC and XOM.
Here's Why You Should Retain Bruker (BRKR) Stock for Now
by Zacks Equity Research
Investors are optimistic about Bruker's (BRKR) segmental results and robust bookings and backlog growth.
Zimmer Biomet (ZBH) Signs Co-Marketing Agreement for HipInsight
by Zacks Equity Research
Zimmer Biomet's (ZBH) HipInsight is a mixed reality-based visualization tool that will aid surgeons in precise implant placement and alignment during total hip replacement.
Here's Why Investors Should Retain Thermo Fisher (TMO) Stock
by Zacks Equity Research
Investors are optimistic about Thermo Fisher's (TMO) better-than-expected results and robust international performance.
Masimo's (MASI) Latest Watch to Improve Patient Outcomes
by Zacks Equity Research
Masimo's (MASI) full-market consumer release of the Masimo W1 and other related launches is likely to significantly improve RPM.
Chemed's (CHE) Roto-Rooter Growth Aids, Macro Challenges Ail
by Zacks Equity Research
Chemed's (CHE) VITAS segment revenue decline during the second quarter gets somewhat offset by a geographically weighted average Medicare reimbursement rate increase of nearly 1.3%.
Here's Why You Should Retain Haemonetics (HAE) Stock Now
by Zacks Equity Research
Investors are optimistic about Haemonetics' (HAE) better-than-expected results and strong Plasma sales.
Haemonetics (HAE) Business Recovery Continues, Macro Issues Ail
by Zacks Equity Research
Despite sluggish results of Haemonetics' (HAE) Blood Center business, Whole Blood revenues grow on favorable order timing among distributors in the Asia Pacific and EMEA.
McKesson (MCK) Up 7.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
McKesson (MCK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Nevro's (NVRO) PDN Therapy Gets Positive Coverage Updates
by Zacks Equity Research
Latest favorable coverage decisions for Nevro's (NVRO) PDN Therapy are expected to serve a wider patient pool.
3 Reasons to Hold Abiomed (ABMD) Stock in Your Portfolio
by Zacks Equity Research
Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.
Here's Why You Should Hold on to Chemed (CHE) Stock Now
by Zacks Equity Research
Investors are optimistic about Chemed's (CHE) better-than-expected earnings and impressive Roto-Rooter results.
Medtronic (MDT) Obtains U.S. Distribution Rights for BioButton
by Zacks Equity Research
Medtronic's (MDT) new deal with BioIntelliSense will ensure accessibility to BioButton for continuous vital sign measurements of general care patients in the United States.
Boston Scientific (BSX) Grows Operationally Amid Macro Issues
by Zacks Equity Research
In the Asia Pacific region, Boston Scientific (BSX) grows operationally with notable performance in Japan, India and the ASEAN countries.
Patterson Companies (PDCO) Q1 Earnings & Sales Miss Estimates
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal first-quarter 2023 results were adversely impacted by unfavorable currency movements.
Cooper Companies (COO) Q3 Earnings & Revenues Top Estimates
by Zacks Equity Research
Despite a decline in the bottom line, Cooper Companies' (COO) fiscal third-quarter earnings reflect solid segmental performance.
Veeva Systems (VEEV) Beats on Q2 Earnings, Revises FY23 View
by Zacks Equity Research
Veeva Systems' (VEEV) fiscal Q2 results reflect impressive performances by both of its segments.
Zacks.com featured highlights include TotalEnergies, J.B. Hunt Transport Services, Archer-Daniels-Midland , McKesson and Republic Services
by Zacks Equity Research
TotalEnergies, J.B. Hunt Transport Services, Archer-Daniels-Midland , McKesson and Republic Services are part of Zacks Screen of the Week article.
Henry Schein (HSIC) Inks Deal to Acquire Midway Dental Supply
by Zacks Equity Research
Henry Schein's (HSIC) acquisition of Midway Dental Supply complements its efforts to offer products and services that deliver more effective, high-quality patient care.
Here's Why You Should Retain AngioDynamics (ANGO) Stock Now
by Zacks Equity Research
AngioDynamics (ANGO) continues to benefit from strength in segments but forex remains a woe.
5 Dividend Growth Stocks to Beat September Slump
by Sweta Killa
Dividend growth stocks like TotalEnergies, J.B. Hunt, Archer-Daniels-Midland, McKesson and Republic Services seem like solid choices for September.
Bruker (BRKR) Debuts Innovations for Proteomics & Metabolomics
by Zacks Equity Research
Bruker's (BRKR) novel nanoElute 2 and next-generation MetaboScape 2023 release are likely to offer enhanced workflows for proteomics and metabolomics applications.
Reasons Why You Should Retain ResMed (RMD) Stock For Now
by Zacks Equity Research
Investors are optimistic about ResMed's (RMD) better-than-expected results and robust device sales.
Haemonetics (HAE) Inks Epic Deal to Expand Hospital Business
by Zacks Equity Research
According to Haemonetics (HAE), amid the complex situation of blood supply and staffing shortages, the SafeTrace Tx transfusion management system is set to provide more transfusion safety and efficiency.